"Ranbaxy denies US FDA allegations," the company Chairman and Managing Director Malvinder Singh told reporters here.
Shares of the drug major today opened five per cent up at Rs 430 and rallied further to touch an intra-day high of Rs 446.55, registering a gain of 9.11 per cent.
Earlier this week, the US Department of Justice had filed a motion against the company in a district court of Maryland alleging fraudulent activities.
Shares of Ranbaxy, which dropped 14.01 per cent to Rs 409.25 yesterday, today surged 7.39 per cent and was later trading at Rs 439.50 on the BSE.
Also Read
Singh also said Ranbaxy's deal with Daiichi Sankyo stands despite charges by the US FDA, stating that the Japanese firm was well aware of the happenings of Ranbaxy with regards to US FDA.
"There is no exit clause in the agreement with Daiichi Sankyo," Singh added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app